English 中文简体 中文繁体



Recent progress in cancer immunotherapy has made a historic breakthrough. With multiple in-house proprietary technology platforms, Alphamab Oncology has established a globally competitive and differentiated pipeline which covers single domain antibody/monoclonal antibodies, multi-functional antibodies, and antibody-drug conjugates. Among them, The world's first subcutaneous PD-L1 inhibitor injection (Envafolimab) has been obtained the market approval by the Chinese National Medical Products Administration, several varieties have entered the critical clinical stage in China and the United States, 2 varieties were selected into the national special project of " New Drug Development", and 3 varieties were granted 4 orphan drug qualifications by FDA.



Pipeline Programs